ATNM-400 demonstrates robust efficacy in prostate cancer tumor models with acquired resistance to Pluvicto ® and enzalutamide, follow-up continues ATNM-400 significantly improved survival compared to the approved prostate cancer treatment Pluvicto ® , the first blockbuster radiotherapy In combination with enzalutamide, an approved ARPI therapy, ATNM-400 produced enhanced efficacy with 40% of prostate cancer tumor-bearing... Read More

ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandi ® (enzalutamide), the ability to overcome Xtandi resistance, and activity in combination ATNM-400 is more efficacious than both Pluvicto ® (177-Lu-PSMA-617) and Ac-225-PSMA-617 targeted radiotherapy in prostate cancer in vitro and in vivo models and overcome resistance in prostate cancer tumors that failed Pluvicto ® therapy... Read More

Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial CAR-T therapy Iomab-ACT supported by results of NIH funded trial with MSK showing effective lymphodepletion of targeted immune cells resulting in negligible rates of CAR-T toxicities ICANS and CRS and CAR T-cell persistence with a novel CD19 CAR-T therapy... Read More

Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists following Pluvicto therapy and ATNM-400 demonstrates sustained tumor control after Pluvicto stops working ATNM-400 showed greater tumor growth inhibition compared to Pluvicto in prostate cancer models with 99.8% tumor growth inhibition... Read More

Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML models Actimab-A is the only CD33 targeted radiotherapy with Actinium-225 isotope payload in development for AML and other myeloid malignancies Actimab-A is currently being advanced in several combination studies including a... Read More

99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy tissues in prostate cancer xenograft model Initial ATNM-400 preclinical data to be presented at AACR including results in Pluvicto resistant prostate cancer models NEW YORK , March 27, 2025 /PRNewswire/ -- Actinium Pharmaceuticals,... Read More

ATNM-400 is a novel, non-PSMA targeting, first-in-class Actinium-225 radiotherapy for prostate cancer with initial preclinical results to be presented at the AACR Annual Meeting Actinium is establishing radiopharmaceutical manufacturing infrastructure in 2025 to support expanding clinical trials and to leverage its proprietary Actinium-225 cyclotron manufacturing technology Data from several clinical trials expected in... Read More

Company to highlight recent significant progress made with its Actimab-A and Iomab-ACT clinical programs, leading-edge R&D and radiopharmaceutical manufacturing infrastructure Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities in myeloid malignancies, solid tumors and cell & gene therapy conditioning with clinical data expected in 2025 supporting each addressable market Presentation... Read More

Actinium will present 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning Dr. Ehab Atallah , Professor of Medicine at the Medical College of Wisconsin to highlight Actimab-A clinical results, mutation agnostic mechanism and backbone therapy potential Clinical proof of concept data from frontline AML trial under NCI CRADA,... Read More

NEW YORK , March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler's high-quality Actinium-225 to further develop its... Read More

NEW YORK , March 20, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that is has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to expand Actimab-A's mutation agnostic mechanism of action. The collaboration has two specific objectives. The first... Read More

Actinium to highlight 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning Clinical proof of concept data expected in 2H:2025 from Actimab-A combination with blockbuster immunotherapies KEYTRUDA ® and OPDIVO ® in solid tumor indications Actimab-A expanded into frontline AML in triplet combination with Venetoclax and... Read More

Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA ® or OPDIVO ® can result in improved patient outcomes MDSCs – Myeloid Derived Suppressor Cells in the tumor microenvironment are believed to reduce effectiveness of PD-1 inhibitors like KEYTRUDA ® and OPDIVO ® Trials supported by preclinical data showing Actimab-A can selectively target and deplete MDSCs which express CD33 Clinical proof... Read More

Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy Mutation agnostic potential of Actimab-A demonstrated by high rates of Complete Remissions and Measurable Residual Disease Negativity in patients with high-risk features including TP53 mutations and prior Venetoclax treatment Actimab-A + CLAG-M combination yielded deep and... Read More

NEW YORK , March 12, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it will participate at the 37 th Annual Roth Conference on March 16 th to 18 th . Actinium management will be in attendance during the conference and will be available for 1-on-1 meetings on March 17 th and 18 th . Interested... Read More

Represents first ever triplet combination using targeted radiotherapy as a backbone therapy in AML with initial clinical data expected in 2H:2025 Expansion into frontline setting greatly expands potential addressable patient opportunity for Actimab-A Triplet combination supported by previously completed Phase 1 trials of Actimab-A + Venetoclax and Actimab-A + CLAG-M demonstrating Actimab-A's mutation agnostic and synergistic... Read More

Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes Two Iomab-ACT INDs cleared by FDA: Commercial CAR-T trial at University of Texas Southwestern and sickle cell transplant... Read More

Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK , Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today... Read More

Iomab-B is the first CD45 targeted radiotherapy for conditioning in development to enable potentially curative bone marrow transplant and represents an alternative to chemotherapy-based approaches SIERRA achieved durable Complete Remission primary endpoint and Event-Free Survival secondary endpoint with high statistical significance Iomab-B was well tolerated in the older, heavily pretreated relapsed/refractory AML patients... Read More

FDA determined that the Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B despite its statistically significant primary endpoint Additional head-to-head randomized clinical trial demonstrating overall survival benefit with Iomab-B is required by FDA to support a BLA filing Actinium to request a meeting with the FDA to further discuss specifics of additional trial Actinium will seek strategic partner... Read More

Newly issued U.S. patent augments Actinium's existing composition of matter patent coverage over Iomab-B and Iomab-ACT targeted radiotherapy conditioning programs Pertains to the use of Iomab-ACT with genetically engineered hematopoietic stem cells for treating non-malignant diseases including sickle cell disease, severe combined immunodeficiency disease, β-thalassemia and Fanconi's anemia NEW YORK , Aug. 1, 2024... Read More

Sickle cell disease affects approximately 100,000 patients in the U.S. annually and is a debilitating and life-threatening condition with high unmet need Current conditioning with non-targeted chemotherapies provides limited access to potentially curative bone marrow transplant and recently approved gene therapies for sickle cell disease patients Initial trial focused on conditioning for bone marrow transplant intended to... Read More

Presentation to highlight positive outcomes of Iomab-B led bone marrow transplant in difficult to treat TP53 patients and the mutation-agnostic mechanism of Actimab-A for patients with relapsed or refractory acute myeloid leukemia Iomab-B and Actimab-A represent the only clinical stage antibody radiation conjugates in development for patients with acute myeloid leukemia NEW YORK , July 25, 2024 /PRNewswire/ -- Actinium... Read More

Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors Combination with leading menin inhibitor demonstrates acute myeloid leukemia cell death and significant tumor elimination not achieved with monotherapy Menin... Read More

Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial Long-term efficacy results in patients with active relapsed or refractory acute myeloid leukemia also observed in the SIERRA trial NEW YORK , June 14, 2024... Read More

Novel targeted radiotherapy-based combination being studied as potential backbone therapy potential relapsed or refractory acute myeloid leukemia Actimab-A + CLAG-M produced high rates of response, measurable residual disease negativity, bone marrow transplant access and improved survival outcomes in high-risk patients including TP53+ and venetoclax treated patients SNMMI oral presentation highlighted dosimetry results and... Read More

Iomab-B led bone marrow transplant improved survival in patients with high-risk relapsed or refractory acute myeloid leukemia including those with a TP53 mutation Iomab-B safely delivered radiation to the target bone marrow at greater amounts than achievable with total body irradiation while sparing healthy non-target organs and enabled 100% access to bone marrow transplant Novel linker technology supports Actinium's... Read More

KOL and principal investigator, Dr. Farrukh Awan , Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern to join Actinium management on the webinar Webinar to be held on Monday, May 20 th at 8:00 AM ET NEW YORK , May 15, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs)... Read More

Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial Long-term efficacy results in older patients with active relapsed or refractory acute myeloid leukemia also observed in the SIERRA trial NEW YORK , May 14, 2024... Read More

Iomab-B and Actimab-A are the only targeted radiotherapies in for acute myeloid leukemia addressing different parts of the patient journey Improved survival demonstrated with both Iomab-B and Actimab-A in patients with high-risk acute myeloid leukemia including those with a TP53 mutation and prior venetoclax treatment Novel linker technology supports Actinium's Antibody Radiation Conjugate pipeline expansion in solid tumor... Read More

Dr. Farrukh Awan , Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern and Principal Investigator for the trial to join Actinium management for webinar Expansion of Iomab-ACT program with commercial CAR-T supported by ongoing MSKCC clinical trial with success implying a potential billion-dollar market opportunity in lymphodepletion Webinar to be held on Monday, May 20 th at 8:00 AM ET... Read More

Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients age 55 and above with high-risk active relapsed or refractory acute myeloid leukemia Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not... Read More

The SIERRA results demonstrate Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis -Represents the eleventh oral presentation of the Phase 3 SIERRA results demonstrating continued recognition of the high potential for Iomab-B led allogeneic bone marrow transplant by the bone marrow transplant community NEW YORK , April 1,... Read More

Potential blockbuster opportunity for next-generation targeted radiotherapy conditioning with CAR T-cell therapy a multi-billion market with six FDA approved therapies totaling sales over $3.5 billion in 2023 and cell and gene therapies forecasted to reach over ninety-thousand patients annually by 2030 Iomab-ACT is the first targeted radiotherapy agent intended to be used to condition patients for cell and gene therapies to... Read More

Actinium's cyclotron produced Actinium-225 material has demonstrated radiochemical and radionuclidic purity identical to current gold-standard methods and has the potential to be significantly lower cost at commercial scale than currently available production methods Proprietary manufacturing technology supported by 5 issued U.S. patents, 49 issued international patents and significant technical know-how Actinium to commit... Read More

Active relapsed or refractory AML patients 65+ years receiving an Iomab-B led Bone Marrow Transplant (BMT) achieved significant improvement in survival at one and two years compared to control arm patients none of whom survived even one year Unprecedented 100% BMT access and engraftment in evaluable patients receiving a therapeutic dose of Iomab-B despite high leukemia burden and multiple lines of prior treatment Iomab-B has... Read More

Iomab-B significantly improved outcomes in TP53 positive patients with a median overall survival of 5.49 months versus 1.66 months in those not receiving Iomab-B (hazard ratio = 0.23, p-value=0.0002) in the Phase 3 SIERRA Trial The results demonstrate Iomab-B's ability to overcome the negative impact of a TP53 mutation in these patients who otherwise would have limited treatment options and dismal prognosis Five... Read More

Two oral presentations and three poster presentations will highlight Iomab-B and Iomab-ACT CD45 targeted conditioning for bone marrow transplant and CAR-T cellular therapy NEW YORK , Jan. 2, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that five abstracts have been accepted for presentation at the... Read More

Relapsed or refractory AML patients with TP53 mutation known to have dismal outcomes due to limited effective treatment options Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) Eighth oral presentation of Iomab-B data since announcement of... Read More

Oral presentation highlighted Iomab-B improves overall survival in patients with TP53 mutation with active, relapsed or refractory AML Eighth oral presentation of the Phase 3 SIERRA results at ASH continues to build broad exposure for Iomab-B across key medical and scientific communities globally NEW YORK , Dec. 11, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader... Read More

Oral presentation to highlight Iomab-B's ability to significantly improve overall survival in patients with relapsed or refractory AML with a TP53 mutation Four presentations in total demonstrating the mutation agnostic efficacy potential of Iomab-B and Actimab-A in relapsed or refractory and elderly AML patients NEW YORK , Dec. 8, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the... Read More

Actimab-A can target CD33 positive immune suppressing myeloid derived suppressor cells and restore T cell proliferation and effector response Solid tumor MDSC infiltration and uptake of Actimab-A confirmed by SPECT/CT imaging in a humanized non-small cell lung cancer model NEW YORK , Nov. 6, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc . (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of... Read More

NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it will be attending Bio-Europe, the largest biopharmaceutical industry partnering event in Europe , taking place November 6 – 8, 2023 in Munich, Germany . Actinium is advancing a pipeline of differentiated, clinical-stage targeted... Read More

Relapsed or refractory AML patients with a TP53 mutation receiving Iomab-B led allogeneic bone marrow transplant had a median Overall Survival of 5.49 months compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) Iomab-B's mutation-agnostic mechanism overcomes TP53 mutations and produced similar median Overall Survival outcomes of 6.37 months in TP53 negative patients and 5.72 months... Read More

Ongoing clinical trial is the first ever to combine targeted radiotherapy conditioning, Iomab-ACT, with CAR-T cell therapy to achieve lymphodepletion along with reduction of cytokine release syndrome and neurotoxicity Targeted conditioning directed at CD45 has the potential to significantly expand the market opportunity for cellular and gene therapies in multiple indications by eliminating or reducing the need for... Read More

NEW YORK , Sept. 27, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details an abstract accepted for poster presentation at the upcoming Society of Immunotherapy of Cancer (SITC) 38 th Annual Meeting, which will be held in San Diego , November 3-5, 2023 . Details of the SITC poster presentation : Abstract... Read More

Extended follow-up in the Actimab-A + CLAG-M trial showed median overall survival in patients proceeding to bone marrow transplant of 24 months in all patients and 30 months in patients who received prior venetoclax treatment Actimab-A shown to enhance the anti-leukemic activity of FLT3 inhibition of approved therapies gilteritinib and midostaurin preclinically, supporting the clinical evaluation of Actimab-A combinations... Read More

First ever data demonstrating anti-leukemic effect of Actimab-A in FLT3 Mutant AML models NEW YORK , Aug. 31, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details three abstracts accepted for poster presentation at the upcoming Society of Hematologic Oncology (SOHO) 2023 Annual Meeting, which will be held in... Read More

NEW YORK , Aug. 21, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details two abstracts accepted for oral and poster presentation at the upcoming European Association of Nuclear Medicine (EANM) 2023 Congress, which will be held in Vienna , September 9-13, 2023 . The EANM oral presentation, reflecting the... Read More

NEW YORK , July 24, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company will participate in the 2nd Annual Targeted Radiopharmaceuticals Summit in Boston , July 25 - 27, 2023 . Actinium will present "Targeted Radiotherapeutics & Innovative Combinations to Alter the Treatment Outcome for... Read More

SNMMI Henry N. Wagner, Jr., Abstract of the Year award represents top selection out of more than 1,500 abstracts accepted for presentation NEW YORK , June 26, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM, 'Actinium'), a leader in the development of targeted radiotherapies, today announced that the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 Annual Meeting selected Abstract 685... Read More

NEW YORK , June 23, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details the six abstracts accepted for oral and poster presentation at the upcoming Society for Nuclear Medicine & Molecular Imaging (SNMMI) 2023 Annual Meeting, which will be held in Chicago , June 24-27, 2023 . These abstracts exhibit the... Read More

NEW YORK , June 16, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company will participate in a fireside chat at the Maxim Healthcare Virtual Conference on Wednesday, June 21, 2023 at 12:30 PM EST . This conference will be webcast live on M-Vest. Sign up here to attend. About Actinium... Read More

NEW YORK , June 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company will participate in a fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023 at 1:30 PM EST . The live webcast of the presentation will be accessible on the investor relations... Read More

SIERRA results demonstrate unprecedented bone marrow transplant access and outcomes with Iomab-B BLA filing for Iomab-B expected by year end 2023 based on positive pivotal Phase 3 SIERRA results NEW YORK , June 12, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announced positive SIERRA trial results in an oral... Read More

NEW YORK , June 7, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it will be added as a member of the small-cap Russell 2000® and all-cap Russell 3000® Indexes as part of the 2023 Russell indexes reconstitution, according to a preliminary list of additions posted May 19 and effective upon the... Read More

Abstracts highlight data pertaining to both Iomab-B and Actimab-A clinical results including the SIERRA Phase 3 trial, dosimetry and machine learning applications for personalized radiotherapy dosing and novel radiotherapy discovery NEW YORK , May 22, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced... Read More

NEW YORK , May 11, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that an abstract has been accepted for oral presentation at the upcoming European Hematology Association 2023 Congress (EHA), which will be held in Frankfurt, Germany June 8-11 , 2023. The abstract includes data from Actinium's SIERRA... Read More

NEW YORK , May 10, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company's management team will participate in 1x1 meetings and deliver a corporate presentation on Monday, May 15, 2023 at 3:20 PM EST at the Guggenheim Healthcare Talks Radiopharmaceuticals Day. The live webcast of the... Read More

24 leading bone marrow transplant (BMT) centers that perform over 30% of transplants in the U.S. participated in the SIERRA trial that enrolled patients with active relapsed or refractory acute myeloid leukemia Demonstration of rapid ability and ease of adoption for Iomab-B infusions at SIERRA sites NEW YORK , April 28, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a... Read More

EBMT oral presentation builds awareness for Iomab-B and the SIERRA trial results with the European transplant community that performs twice as many transplants compared to the U.S. Iomab-B enabled unprecedented 100% bone marrow transplant access and engraftment with 75% post-BMT CR rate in patients with active, relapsed or refractory acute myeloid leukemia who are considered unfit and transplant ineligible in routine... Read More

Highly significant (p<0.0001) reduction in tumor volume in ovarian cancer model when using HER3-ARC conjugated to either Actinium-225 or Lutetium-177 compared to bevacizumab (Avastin) HER3 is expressed at high levels within multiple solid tumors and has been linked to poor survival and drug resistance, providing strong rationale for HER3 targeted radiotherapy in a clinical setting NEW YORK , April 19, 2023 /PRNewswire/ --... Read More

Actimab-A displayed robust MDSC depletion at statistically superior levels to other CD33-targeted therapeutics, including unconjugated Lintuzumab and Mylotarg ™ Myeloid derived suppressor cells (MDSCs) are ubiquitous across multiple cancer indications and exert strongly immunosuppressive effects through inhibition of immune responses by T cells, B cells and NK cells Data support the potential for Actimab-A to be a backbone... Read More

Announced positive results from the pivotal Phase 3 SIERRA trial of Iomab-B in r/r AML patients ages 55+; achieved primary endpoint of dCR with high statistical significance (p<0.0001) On track to commence Early Access Program and file a BLA submission for Iomab-B in 2H:2023 Actimab-A + CLAG-M demonstrated 59% 1-year and 32% 2-year survival in r/r AML patients subset that failed venetoclax; NCI CRADA provides broad support... Read More

First ever data demonstrating the novel application of Actimab-A to enhance antitumor immune activity by depleting MDSCs, a population of highly immunosuppressive cells closely associated with poor clinical outcomes in cancer New solid tumor program data including the first exploration of the effects of targeting HER3 with either alpha (225Ac)- or beta (177Lu)- emitting radiotherapeutics in ovarian and colorectal cancer... Read More

NEW YORK , March 15, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company's management team will participate in a virtual presentation at Oppenheimer's 33 rd Annual Healthcare Conference being held March 13-17, 2023 . The presentation will include recent Company highlights including... Read More

KOL webinar on Tuesday, February 28, 2023 , at 8 a.m. EST Actinium intends to file a BLA for Iomab-B in 2H:2023 following positive SIERRA trial results Actinium reiterates current cash and cash equivalents of approximately $100 million are projected to fund operations through 2025 NEW YORK , Feb. 27, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the... Read More

In patients achieving 6-month dCR with Iomab-b, 1-year survival of 92% and 2-year survival of 60% was achieved; median overall survival (OS) has not been reached in these patients Iomab-B demonstrated significant improvement in Event Free Survival (EFS) with a Hazard Ratio = 0.22, p<0.0001 Iomab-B doubled 1-year survival and median overall survival compared to control arm patients who did not crossover Iomab-B was well... Read More

Late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023 , to feature Iomab-B SIERRA Pivotal Trial results Investor call at 6:00 PM EST on Saturday, February 18, 2023 , to highlight full results from the Phase 3 SIERRA trial NEW YORK , Feb. 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today... Read More

National Cancer Institute will sponsor and oversee clinical trials of Actimab-A under the terms of the Cooperative Research and Development Agreement Collaboration will provide Actimab-A and other necessary support to study Actimab-A alone or in combinations with chemotherapy, immunotherapy and/or targeted agents aligned with Actinium's development strategy Over 2,000 institutions within NCI funded extramural clinical... Read More

NEW YORK , Jan. 17, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company's management team will participate in a fireside chat on Thursday, January 19, 2023 at 10:30 AM EST at the 3 rd Annual B. Riley Securities Oncology Conference. The webcast of the presentation will be accessible on the... Read More

Full Iomab-B SIERRA data set to be presented in late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023 Company to host conference call and webcast on Saturday, February 18, 2023 , at 6:00 PM EST SIERRA trial met primary endpoint with high statistical significance (p<0.0001) Company to host Iomab-B KOL event with Dr. Sergio Giralt of Memorial Sloan Kettering Cancer Center at 8:00 AM EST on February 28, 2023... Read More

59% 1-year overall survival and 32% 2-year overall survival in patients with prior Venetoclax treatment 52% 1-year overall survival and 19% 2-year overall survival in patients with a TP53 mutation 75% measurable residual disease negativity achieved in heavily pretreated, high-risk relapsed or refractory patients Actimab-A + CLAG-M was well tolerated with a manageable safety profile NEW YORK , Dec. 12, 2022 /PRNewswire/ --... Read More

Collaboration builds on the groundbreaking research of Columbia University oncologist Dr. Siddhartha Mukherjee that uses gene-editing to remove the CD33 surface protein from hematopoietic stem cells Actimab-A to be used post-transplant of these engineered stem cells to prevent relapse by selectively targeting residual CD33 positive leukemia cells while sparing the engineered stem cells High rates of measurable residual... Read More